AYTU

Handel nachbörslich: 1.25

Aytu Biopharma Inc (AYTU)

Überblick Nachrichten Preisverlauf Financials Warum fällt AYTU? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Aytu Biopharma Inc Stock (AYTU) Company Profile

Aytu Biopharma Inc

Healthcare (1153)

(720) 437-6580

7900 E. UNION AVENUE, DENVER

@aytubioscience

Nächster Verdiensttermin

Neueste SEC-Einreichungen

AYTU's Discussions on Twitter

Vergleichen Sie AYTU mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
AYTU Aytu Biopharma Inc	1.25	8.08M	93.76M	-13.68M	8.77M	-2.63
ZTS Zoetis Inc	159.27	70.23B	9.29B	2.52B	2.28B	5.57
HLN Haleon Plc Adr	10.74	48.23B	14.35B	1.85B	0	0.4023
TAK Takeda Pharmaceutical Co Adr	14.36	48.22B	30.08B	710.16M	4.45B	0.2182
TEVA Teva Pharmaceutical Industries Ltd Adr	16.93	18.57B	16.54B	-1.64B	749.00M	-1.45
UTHR United Therapeutics Corp	301.42	13.29B	2.76B	1.11B	898.10M	22.77

Aytu Biopharma Inc Stock (AYTU) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2021-03-30	Eingeleitet	Cantor Fitzgerald	Overweight
2020-05-29	Eingeleitet	H.C. Wainwright	Buy

Aytu Biopharma Inc Aktie (AYTU) Neueste Nachrichten

Finanzdaten der Aytu Biopharma Inc-Aktie (AYTU)

Aytu Biopharma Inc (AYTU)

Aytu Biopharma Inc Stock (AYTU) Company Profile

Vergleichen Sie AYTU mit anderen Aktien

Aytu Biopharma Inc Stock (AYTU) Upgrades & Downgrades

Aytu Biopharma Inc Aktie (AYTU) Neueste Nachrichten

Aytu BioPharma to Participate in the Lytham Partners Summer 2022 Investor Conference - ACCESS Newswire

Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational a - GuruFocus

Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational and Financial Results on May 14, 2025 - ACCESS Newswire

Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Price Is Right But Growth Is Lacking After Shares Rocket 27% - simplywall.st

Press Release Distribution & PR Platform - ACCESS Newswire

Aytu BioPharma Announces Closing of $4.0 Million Public Offering Priced At-the-Market - ACCESS Newswire

Aytu BioPharma at Planet MicroCap: Strategic Realignment and Growth By Investing.com - Investing.com Canada

Aytu BioPharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025 | AYTU Stock News - GuruFocus

Aytu BioPharma Stock Price, Quotes and Forecasts - Benzinga

Aytu BioPharma CEO Reveals Growth Strategy at Exclusive Vegas Investor Showcase - Stock Titan

Aytu BioPharma, Inc. (NASDAQ:AYTU) On The Verge Of Breaking Even - simplywall.st

Aytu BioPharma Announces Pricing of $4.0 Million Public Offering Priced At-The-Market and the Appointment of a New Director - ACCESS Newswire

AYTU stock touches 52-week low at $1.13 amid market challenges - Investing.com India

Vascular Ehlers-Danlos Syndrome Market Growth Projections - openPR.com

Aytu BioPharma Strengthens Leadership Team with Appointment of Richard Eisenstadt as Chief Financial Officer - ACCESS Newswire

AYTU stock touches 52-week low at $1.2 amid market challenges - Investing.com Australia

AYTU BIOSCIENCE, INC : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K) - Marketscreener.com

AYTU stock touches 52-week low at $1.23 amid market challenges - Investing.com Australia

Insider Buying: Joshua Disbrow Acquires 15,000 Shares of Aytu Bi - GuruFocus.com

Aytu Biopharma CEO Joshua Disbrow buys $19,500 in stock - Investing.com India

Aytu Biopharma CEO Joshua Disbrow buys $19,500 in stock By Investing.com - Investing.com South Africa

AYTU BIOPHARMA CEO Acquires 15,000 Shares - TradingView

Aytu BioPharma Reports Second Quarter of Fiscal Year 2023 - ACCESS Newswire

Aytu BioPharma Regains Nasdaq Minimum Bid Price Compliance - ACCESS Newswire

Aytu BioPharma Reports Record Fourth Quarter and Fiscal Year 2022 Revenue - ACCESS Newswire

Earnings call transcript: Aytu BioPharma Q2 2025 sees revenue dip, strategic shifts - MSN

AYTU stock touches 52-week low at $1.3 amid market challenges - Investing.com Australia

AYTU stock touches 52-week low at $1.3 amid market challenges By Investing.com - Investing.com South Africa

Can This New Board Member Transform Evoke Pharma's Commercial Success? - StockTitan

Aytu BioScience and Neos Therapeutics Announce Special Meetings of Stockholders Related to Proposed Merger to Be Held on March 18, 2021 - ACCESS Newswire

Aytu BioPharma anticipates positive cash flow with ADHD growth and $2M annual cost savings - MSN

Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Second Year in a Row - ACCESS Newswire

Aytu BioPharma’s Imminent Breakthrough: Can It Reach Profitability? - Mi Valle

Loss-Making Aytu BioPharma, Inc. (NASDAQ:AYTU) Set To Breakeven - Yahoo Finance

Aytu BioPharma Inc (AYTU) Q2 2025 Earnings Call Highlights: Stro - GuruFocus.com

Aytu BioScience Earnings Call: Growth Amid Challenges - TipRanks

Denver biotech cuts $500K check when it parted ways with its CFO - The Business Journals

Aytu BioPharma Inc (AYTU) Q2 2025 Earnings Call Highlights: Strong Cash Position and Strategic ... By GuruFocus - Investing.com Canada

Aytu BioPharma, Inc. (NASDAQ:AYTU) Q2 2025 Earnings Call Transcript - Insider Monkey

Aytu BioPharma Reports Strong Q2 Earnings Growth - TipRanks

Aytu BioPharma Inc. (AYTU) reports earnings - Quartz

AYTU BIOPHARMA, INC SEC 10-Q Report - TradingView

Aytu BioPharma Reports Fiscal 2025 Second Quarter Results - TradingView

Aytu BioPharma Reports Fiscal 2025 Second Quarter Operational and Financial Results - ACCESS Newswire

Finanzdaten der Aytu Biopharma Inc-Aktie (AYTU)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie AYTU